Mosaic TX
United Kingdom
- Hinxton, Cambridgeshire
- 05/04/2023
- Series A
- $28,000,000
ABOUT US
Mosaic Therapeutics is an oncology therapeutics company using advanced computational methods and next-generation cancer models to discover and develop novel targeted therapies. The company’s main mission is to tackle cancers with substantial unmet need by reinventing the traditional approach to target and drug discovery.
Born out of pioneering research at the Wellcome Sanger Institute in collaboration with the Netherlands Cancer Institute, and anchored around a proprietary platform that has seen 20 years of fine-tuning and development, Mosaic has active programmes across a variety of oncology indications and disease biology pathways
- Industry Biotechnology
- Website https://www.mosaic-tx.com/
- LinkedIn https://www.linkedin.com/company/mosaic-tx/
Related People
Brian GladsdenFounder
United Kingdom -
ND
An inspiring, purpose-driven leader, unleashing the power of science and people to improve human health.
NuCube Energy | $13,000,000 | (Feb 20, 2026)
Stacks | $23,000,000 | (Feb 20, 2026)
PolyGone Systems Inc | $4,000,000 | (Feb 20, 2026)
Altesa BioSciences, Inc. | $75,000,000 | (Feb 20, 2026)
SPRX | $31,000,000 | (Feb 20, 2026)
Adronite | $5,000,000 | (Feb 20, 2026)
Odynn | $9,500,000 | (Feb 20, 2026)
Ascent(US) | $45,000,000 | (Feb 20, 2026)
Ownwell | $50,000,000 | (Feb 20, 2026)
Badge | $17,100,000 | (Feb 20, 2026)
Sift Biosciences | $3,700,000 | (Feb 19, 2026)
Avantos.ai | $25,000,000 | (Feb 19, 2026)